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Abstract
Background:  Ventricular assist devices(VAD) implantation/removal is a complex surgical
procedure with perioperative bleeding complications occurring in nearly half of the cases.
Recombinant activated factor VII (rFVIIa) has been used off-label to control severe hemorrhage in
surgery and trauma. We report here our experience with rFVIIa as a rescue therapy to achieve
hemostasis in patients undergoing orthotopic heart transplant (OHT) and/or VAD implantation.
Methods: A retrospective review was conducted from Jan 03 to Aug 05 for patients who received
rFVIIa for the management of intractable bleeding unresponsive to standard hemostatic blood
component therapy. Blood loss and the quantity of blood products, prior to, and for at least 12
hours after, administration of rFVIIa were recorded.
Results: Mean patient age was 53, (38–64 yrs), mean dose of rFVIIa administered was 78.3 µg/kg
(24–189 µg/kg) in 1–3 doses. All patients received the drug either intraoperatively or within 6
hours of arrival in ICU. Mean transfusion requirements and blood loss were significantly reduced
after rFVIIa administration (PRBC's; 16.9 ± 13.3 to 7.1 ± 6.9 units, FFP; 13.1 ± 8.2 to 4.1 ± 4.9 units,
platelets; 4.0 ± 2.8 to 2.1 ± 2.2 units, p < 0.04 for all). 5 patients expired including 3 with
thromboembolic cause. One patient developed a lower extremity arterial thrombus, and another
deep vein thrombosis.
Conclusion: In this review, there was a significant decrease in transfusion requirement and blood
loss after rFVIIa administration. Although, 5/17 developed thromboembolic complications, these
patients may have been at higher risk based on the multiple modality therapy used to manage
intractable bleeding. Nevertheless, the exact role of rFVIIa with respect to development of
thromboembolic complications cannot be clearly determined. Further investigation is needed to
determine rFVIIa's safety and its effectiveness in improving postoperative morbidity and mortality.
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Background
Ventricular assist devices (VADs) have been in widespread
clinical use for long-term support of patients with end-
stage heart failure as a bridge to transplantation. These
devices are compatible with low long term morbidity,
hemodynamic stability along with significant metabolic
and physical rehabilitation. However, VAD implantation
and explantation are complex surgical procedures with
perioperative bleeding occurring in nearly half of the cases
[1,2]. The amount of blood and blood products used dur-
ing these operations is substantial, and cardiac surgery
including VAD implantation/explantation now account
for approximately 15% of the yearly utilization of the
entire banked blood supply in both the US and the UK
[3,4]. In addition to issues related to cost and availability
of blood and blood products, large volume blood product
transfusions are associated with the risk for transfusion-
related reactions, infectious complications, increased pul-
monary vascular resistance, possible alloreactivity against
transplanted organs, and even lower long-term survival
well outside the perioperative period [5].
Further in patients undergoing complex cardiac surgeries
requiring re-explorations [6-9], only 50% of the patients
had a surgical source of bleeding which demonstrates the
important role of acquired hemostatic abnormalities that
result in diffuse, microvascular bleeding. In addition, the
analysis by Moulton et al demonstrated that excessive
bleeding is the most likely cause of increased mortality
since mortality was also increased by three-fold when
patients who were not re-explored bled more than two lit-
ers within the first 24 hours after surgery [6]. Excessive
bleeding requiring transfusion may also result in other
complications such as stroke and may affect long term
mortality. In a large, recently published analysis, excessive
bleeding requiring more than four units of PRBC transfu-
sion was the strongest (odds ratio = 5) independent pre-
dictor with respect to perioperative stroke [10]. In yet
another study, massive blood loss (receiving at least five
units of PRBC within 24 hours of surgery) in cardiac sur-
gery was associated with an 8.1-fold (95% confidence
interval, 3.9–17.0) increase in the odds of death [9].
Recombinant Factor VIIa (rFVIIa, NovoSeven®, Novo Nor-
disk Inc, Princeton, NJ) is a potent clotting factor currently
FDA-approved only for the control of bleeding in hemo-
philiacs with factor VIII (FVIII) or factor IX (FIX) inhibi-
tors or patients with Factor VII deficiency. rFVIIa is
increasingly being used off-label for control of coagulo-
pathic bleeding unresponsive to conventional measures
in cardiac surgical patients [3,4,11-15]. In our retrospec-
tive case series, we report our experience with the use of
rFVIIa in the treatment of refractory bleeding in patients
with VAD implantation or explantation and orthotopic
heart transplant (OHT).
Methods
Following institutional review board approval, we con-
ducted a retrospective chart review from January 2003 to
August 2005 involving patients who had either VAD
implantation or explantation and OHT. At our institution
cardio-pulmonary bypass (CPB) was performed using a
non-coated circuit and a membrane oxygenator. Anticoag-
ulation was generally achieved with unfractionated
heparin and anticoagulation was monitored with kaolin
activated clotting time (ACT) and whole blood heparin
levels (i.e., via Hepcon automated protamine titration
method, Medtronic, Minneapolis, MN) every 30 minutes
with a target of ≥ 480 seconds and/or a whole blood
heparin level ≥ than the baseline level associated with a
therapeutic ACT prior to initiation of CPB as previously
described [16]. Only one patient with a history of recent
HIT underwent CPB with bivalirudin. All patients without
renal dysfunction received aprotinin (25,000 U/kg or 3.5
mg/kg for both the loading and CPB doses with 1/4 of that
dose every hour by infusion) after heparinization. During
CPB the hematocrit (Hct) was maintained between 0.21
to 0.25. After CPB, the cutoff values for red cell transfu-
sion was Hct < 0.30, for fresh frozen plasma (FFP) and
platelets were based on the initial platelet count, pro-
thrombin time (PT) and activated partial thromboplastin
time (aPTT) as previously described [17]. Patients who
had continued bleeding and uncorrected coagulopathy
after complete reversal of heparin with protamine and
had received standard conventional component blood
therapy were identified. Conventional component ther-
apy was administered taking into account the effect of
CPB on platelets and coagulation factors. Seventeen such
patients were identified. The decision to give rFVIIa was
based on individual physician discretion. In general, the
decision to administer rFVIIa was based on continued
bleeding related to coagulopathy with no identifiable sur-
gical source. In all cases, patients had received hemostatic
blood components in an attempt to reverse coagulopathy
but bleeding persisted.
Patient characteristics, rFVIIa dose, clinical outcomes and
complications including thrombotic episodes were noted.
All blood loss prior to, and for at least 12 hours after,
administration of rFVIIa was recorded. Complete blood
counts and coagulation studies were obtained to assess for
ongoing hemorrhage and/or coagulopathy. Furthermore,
the amount of blood and hemostatic blood products each
patient received were recorded both before and after
receiving rFVIIa.
Complete data on blood product utilization and bleeding
was available for 15 subjects who were included in the
analysis. Mortality data was available for all 17 patients.
During the study period a total of 200 such procedures
(VADs:134 and OHT: 66) were performed at our institute.Journal of Cardiothoracic Surgery 2007, 2:32 http://www.cardiothoracicsurgery.org/content/2/1/32
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Student's t-test was used to compare values. Unless other-
wise indicated, all values are represented as Mean ± Stand-
ard Deviation.
Results
Demographic and Surgical Data
The demographic and surgical data are illustrated in table
1. The mean age of the patients was 53 years (range; 38–
67 years) and majority (73%) were male. All patients were
Caucasians. None of the patients had a history of a pre-
existing coagulopathy. Two patients had heparin-induced
thrombocytopenia (HIT); one with a known history and
another diagnosed subsequent to thrombocytopenia fol-
lowing the left VAD (LVAD) implantation. Majority of the
patients (9/15) had removal of the bridging VAD fol-
lowed by OHT. Five patients had VAD implantation
(three as destination therapy, two for post-cardiotomy
shock), while one patient had only orthotopic heart trans-
plant (OHT). In one of the patients bridged to transplant
with a LVAD, post transplant allograft failure necessitated
placement on extracorporeal membrane oxygenation
(ECMO) support.
Recombinant Activated Factor VII dose
Complete data was available for 15/17 patients. Eight
received rFVIIa intraoperatively, while seven received it
within six hours of arriving in the cardiothoracic intensive
care unit. The mean total dose of rFVIIa administered was
78.3 µg/kg (range, 24–189 µg/kg). All patients received at
least one dose of rFVIIa with a maximum of three. There
were no strict criteria regarding the dose of rFVIIa and the
dose was based on consultation with transfusion medi-
cine/hematology service and previously published guide-
lines [18]. Initial average rFVIIa dose administered was
40.1  µg/kg (range; 16–85.7 µg/kg). 9/15 patients were
given a second dose for continued bleeding after the first
dose. The average rFVIIa dose was 40.7 µg/kg (range; 12–
79  µg/kg). Four patients continued to bleed after two
doses and received a third dose; average 31.5 µg/kg
(doses: 4.3 – 79 µg/kg). The patient that received the third
dose of 79 µg/kg was the one who received the highest
total dose of 189 µg/kg. This patient had HIT and devel-
oped a macrothrombi in the CPB circuit (within reservoir)
during the conduct of the operation. The patient subse-
quently received multiple bolus doses of bivalirudin and
post-operatively continued to bleed. None of the patients
received rFVIIa prophylactically. Seven of the 15 patients
(47%) required operative re-exploration for continued
hemorrhage, but a surgical source of bleeding could be
identified in only two of these patients.
rFVIIa results in decreased blood loss and decreased 
transfusion requirement
Complete data was available for 15/17 patients. Blood
loss was measured for each patient from the initiation of
surgery and prior to, and for at least twelve hours after
Table 1: Patient demographics, rFVIIa dose, mortality and thrombo-embolic complications
Pt Sex Age 
(yrs)
1st Dose 
(mg)
2nd Dose 
(mg)
3rd Dose 
(mg)
Total rFVIIa 
(µg/kg)
Procedure* Death Cause of 
Death
TE 
episode
Associated Risk 
Factors
1 M 51 7.2 4.8 - 143 VAD to OHT Y Graft Failure N N
2M 5 3 2 . 4 - - 2 4 V A D  t o  O H T N - N N
3M 4 2 2 . 4 - - 3 6 V A D N - Y  ( A T Ψ)N
4 M 52 4.8 4.8 - 77 VAD to OHT Y CVA** 
(embolic)
Y Atherosclerosis
5 M 61 2.4 1.2 - 36 VAD N - N HIT^
6M 6 4 4 . 8 - - 7 2 V A D  t o  O H T N - N N
7M 6 2 4 . 8 - - 5 6 V A D  t o  O H T N - Y  
(DVT)¥
N
8 M 53 2.4 2.4 1.2 80 VAD Y CVA (air 
embolism)
?N
9M 5 7 2 . 4 2 . 4 1 . 2 7 1 O H T N - N N
10 M 53 4.8 - - 48 VAD to OHT N - N N
11 F 38 1.2 1.2 - 32 VAD to OHT N - N N
12 F 51 2.4 6 6 189 VAD Y CVA 
(embolic)
YH I T ^
13 F 67 4.8 2.4 - 109 VAD Y Heart 
Failure
NY  ( M u l t i o r g a n  
failure), ABIOMED#
14 F 46 4.8 4.8 1.2 150 VAD to OHT N - N N
15 M 49 4.8 - - 49 VAD to OHT N - N N
*VAD = ventricular assist device, OHT = orthotopic heart transplant
**CVA = cerebro-vascular accident
€TE = thrombo-embolic
ΨAT = Right lower extremity arterial thrombus
¥DVT = Deep vein thrombosis
^HIT = Heparin induced thrombocytopenia, #ABIOMED = ABIOMED Left Ventricular Assist DeviceJournal of Cardiothoracic Surgery 2007, 2:32 http://www.cardiothoracicsurgery.org/content/2/1/32
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administration of rFVIIa. The blood loss prior to adminis-
tration of rFVIIa was an average of 698 ± 285 ml/hr
(median: 584 ml/hr). This blood loss dropped signifi-
cantly to 186 ± 146 ml/hr (p = 0.001; median: 147 ml/hr)
for the first six hours and 136 ± 127 ml/hr (p < 0.001;
median: 108 ml/hr) for twelve hours immediately after
administration of the drug (Table 2). The average pre- and
post-treatment INR values were 2.34 ± 0.91 and 1.44 ±
0.93 (p = 0.001), with PTTs of 83.8 ± 43.4 and 53.7 ± 16.8
seconds (p = 0.030), respectively. The average hematocrit
before (0.27 ± 0.79) and after rFVIIa administration were
not significantly different (p = 0.175). Similarly the aver-
age platelet counts before (116 ± 71) and after (122 ± 51)
rFVIIa administration were not significantly different (p =
0.379). This was likely secondary to ongoing resuscitative
efforts.
Mean transfusion requirements were significantly
reduced, as patients received an average of 16.9 ± 13.3
(median: 14) units of packed red blood cells (PRBC), 13.1
± 8.2 (median: 12) units fresh frozen plasma (FFP), 4.0 ±
2.8 (median: 3) units platelets and 6.3 ± 6.3 (median: 4)
units cryoprecipitate before dosing but only 7.1 ± 6.9
(median: 7), 4.1 ± 4.9 (median: 2), 2.1 ± 2.2 (median: 1),
and 0.3 ± 0.6 (median: 0) respective units of these blood
products afterward (all p < 0.04) (table 2).
Mortality and thrombotic complications
Mortality rate in this series of patients was 29% (5/17,
table-2). One patient died from acute allograft failure that
failed to recover with ECMO support. A second patient
had undergone an aortic valve replacement at an outside
institution and had been placed on an ABIOMED (ABI-
OMED, Danvers, MA) LVAD for temporary mechanical
support and died from complications associated with
multisystem organ failure. Three other patients died sec-
ondary to massive cerebrovascular accidents. One patient
had HIT and was thus anticoagulated with bivalirudin on
cardiopulmonary bypass. During the operation thrombus
developed in the cardiopulmonary circuit and probably
was the likely source for cerebral thromboembolism.
Another patient was known to have atherosclerosis of the
aorta and had also under gone a 35 minute period of cir-
culatory arrest to reconstruct the distal aorta after iatro-
genic injury during surgery. The third patient suffered
intraoperative air embolism during LVAD implantation.
Peripheral thrombotic complications involved one
patient who developed an isolated lower extremity arterial
thrombus, which was successfully treated via surgical
thrombectomy and a second patient who suffered from an
uncomplicated lower extremity deep venous thrombosis
ten days after rFVIIa administration. Both of these patients
were discharged from the hospital without further com-
plication.
Discussion
rFVIIa is a potent clotting factor that is currently FDA-
approved only for the treatment of severe bleeding epi-
sodes in hemophiliacs with factor inhibitors or patients
with FVII deficiency, although numerous reports are now
appearing in the literature describing its off-label periop-
erative use in the management of diffuse hemorrhage not
amenable to surgical control. The precise mechanism by
which rFVIIa works is not completely clear, however in
vitro  studies investigating the mechanism of action of
rFVIIa postulate that it involves generation of thrombin
by initial binding to tissue factor and subsequent activa-
tion of factor X (FXa) on the platelet surface (i.e. a phos-
pholipid surface); FXa in combination with activated
factor V (i.e. prothrombinase complex) leads to thrombin
formation. This occurs in the absence of factor VIII or fac-
tor IX. [19-21]. The extent of thrombin activation relates
to the concentration of activated factor VII achieved. Par-
tial thrombin generation occurs at rFVIIa concentrations
approximating 50 nM, whereas full activation of
thrombin, referred to as a "thrombin burst", is achieved
Table 2: Blood loss, transfusion requirement, laboratory values prior to and following rFVIIa administration
Before rFVIIa Treatment After rFVIIa Treatment p Value
Blood Loss (ml/hr) 698 ± 285 -
6 Hour Blood Loss (ml/hr) - 186 ± 146 0.001*
12 Hour Blood Loss (ml/hr) - 136 ± 127 <0.001*
Packed Red Cells (Units) 16.9 ± 13.3 7.1 ± 6.9 0.037
Single Donor Platelets (Units) 4.0 ± 2.8 2.1 ± 2.2 0.024
FFP (Units) 13.1 ± 8.2 4.1 ± 4.9 <0.001
Cryoprecipitate (Units) 6.3 ± 6.3 0.3 ± 0.6 0.006
Hematocrit 0.27 ± 0. 79 0.29 ± 0.53 0.175
Platelet Count (x103/dL) 116 ± 71 122 ± 51 0.379
PT (seconds) 21.4 ± 4.8 14.9 ± 3.5 <0.001
INR 2.34 ± 0.91 1.44 ± 0.93 0.001
PTT (seconds) 83.8 ± 43.4 53.7 ± 16.8 0.030
* p-value calculated as compared to blood loss before rVIIa administrationJournal of Cardiothoracic Surgery 2007, 2:32 http://www.cardiothoracicsurgery.org/content/2/1/32
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with higher levels (100 to 150 nM)[22]. This pronounced
thrombin activity on thrombin-activated platelet surfaces
leads to a stabilized thrombin plug and tight fibrin struc-
ture resistant to lysis [23]. This experimental evidence sup-
ports the concept that rFVIIa is potentially safe with
minimal thrombo-embolic complication because it is
effective at sites of vascular injury where there is localized
expression of tissue factor and activated platelets. How-
ever, the thrombotic risks associated with rFVIIa may be
theoretically increased in clinical situations when there is
systemic (e.g. disseminated intravascular coagulation) or
localized (atherosclerotic plaque) pathologic expression
of tissue factor, and or circulating activated platelet micro-
particles [24].
rFVIIa has been shown to be highly effective in correcting
coagulopathy in patients with clotting factor deficiencies
and/or neutralizing antibodies to coagulation cascade
proteins. In such a population, as of 2003, several thou-
sand patients had received over 700,000 doses with com-
plications reported in only 1–2% of cases[25,26] The
most frequently encountered complications included
thromboembolic events, myocardial infarction, and dis-
seminated intravascular coagulation, although any direct
relationship between the administration of rFVIIa and the
latter two adverse events is vague at best due to predispos-
ing or pre-existing factors in the affected patients[27,28]
Currently, it is unclear whether rFVIIa is safe and can effec-
tively correct acquired coagulopathy in critically ill cardiac
and thoracic surgery patients without the increasing the
risk of thromboembolic complications[28,29]
To date, six randomized, placebo-controlled, double-
blind studies including all surgical patients have been
published, with two of these coming from the same
group[4,30-33] Two of these studies report significant
decreases in both the number of patients requiring mas-
sive (>10 units PRBC) transfusion, and in the total units
of transfused blood [4,32]. Two studies showed a non-sig-
nificant trend toward similar results [32,33], and the last
two showed no significant differences between the treat-
ment and placebo groups [30,31]. One of the trials that
did show significant reduction in transfusion require-
ments involved only cardiac surgical patients, but none of
the subjects underwent transplant or VAD implantation/
explantation[4]. None of the six trials showed any signifi-
cant increase in the number of adverse events in patients
receiving rFVIIa. However, recent studies have demon-
strated an increased incidence of thrombo-embolic com-
plications associated with rFVIIa administration[34,35].
VAD insertion is a complex surgical procedure with peri-
operative bleeding occurring in nearly half the cases [1],
and also associated with long term thromboembolic com-
plications based on the type of the implant used[2]. The
current literature addressing the use of off-label rFVIIa in
cardiac surgery patients consists of isolated case reports of
only a single subject at a given institution[13-
15,28,29,36-45] has been reviewed by Despotis et al[46]
Eight such studies deal with cardiac transplantation and/
or VAD placement [47-54] Most of these single case
reports indicate that rFVIIa administration resulted in sig-
nificant decrease in bleeding without any thromboem-
bolic events. One patient developed fatal, diffuse
intravascular thrombosis during administration of FEIBA
after receiving two doses of rFVIIa several hours prior[29]
Of the studies involving multiple patients with rFVIIa
administration during or after cardiac surgery; [13-15],
[55-66], five address those undergoing OHT (eight
patients total) or VAD/ECMO placement (14 patients
total). In four of the five studies there were some throm-
boembolic adverse events occurring after rFVIIa adminis-
tration [57,58,60,61]
In our evaluation of 17 patients undergoing OHT and/or
VAD placement, we are able to demonstrate a significant
improvement in virtually every measure of effective
hemostasis following administration of between 24 and
189 µg/kg of rFVIIa. Most importantly, these parameters
that showed improvement included six and twelve hour
blood loss, units of blood transfused, and PT/PTT values.
This is consistent with a recent review of the literature for
use of rFVIIa following cardiac surgery[46] Unfortunately,
despite such dramatic improvement in clinical values, our
patient population still had an overall 29% (5/17) mor-
tality rate, with two of those deaths occurring within 24
hours of receiving the treatment. One patient died from
acute allograft failure that failed to recover with ECMO
support. Another patient died due to multiorgan failure
following an emergency VAD placement. Three patients
died secondary to massive cerebrovascular accidents.
Although there were pre-existing clinical features increas-
ing the risk of thrombosis in 3/5 patients, rFVIIa was
administered in all the cases only after at least two rounds
of conventional hemostatic therapy failed to stop the
bleeding. This acute mortality is likely reflective not only
of the critically ill nature of our patients in general, but
also the very large volume of transfused blood products,
and associated coagulopathy, prior to administration of
rFVIIa. The limited finding in this subset of our patients is
consistent with the findings of other studies that had used
rFVIIa when conventional hemostatic therapy failed to
stop hemorrhage [67,68]. Of the three patients that died
of massive strokes, two were confirmed to be embolic
although one was clearly related to HIT and the other had
significant risk factors for atheroembolism.
Two patients had peripheral thrombotic complications.
The patient that developed a lower extremity thrombus
had LVAD implantation along with aortic root homograftJournal of Cardiothoracic Surgery 2007, 2:32 http://www.cardiothoracicsurgery.org/content/2/1/32
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following an aortic valve redo operation with an aortic
root abscess secondary to bacterial vegetations on the aor-
tic valve. Another patient had DVT ten days after rFVIIa
administration. His post-op course was complicated by a
low cardiac index requiring intra-aortic balloon, episodes
of atrial fibrillation and acute renal failure requiring
hemodialysis before developing DVT.
All these patients had other reasons for the thromboem-
bolic events however, significant thromboembolic com-
plications could certainly be a result of the administration
of rFVIIa, and they speak strongly to the necessity of fur-
ther controlled studies to evaluate the drug in the setting
of these complex, critically ill patients.
A summary report of adverse events (AE) including
thromboembolic events following administration of
rFVIIa to FDA adverse event reporting system (AERS
1999–2005) was recently published[34] There were 599
AE during this time period of which 220 were throm-
boembolic, in more than 10,000 patients (patient expo-
sure based on a commercially-derived estimate, Premier
Healthcare Informatics, Premier Inc, Charlotte, NC). A
vast majority of this thromboeombolic events occurred
following off-label use of rFVIIa. Of the 220 thromboem-
bolic AE, there were 67 mortalities (30%) and 67% (45/
67) of these deaths were thought to be related to the
thromboembolic complication. The frequency of the
thromboembolic AE cannot be determined from this
data, since the reporting to AERS is purely voluntary and
many AE are not reported.
Karkouti et al in their study comparing the outcomes of
cardiac surgery patients that received rFVIIa for refractory
bleeding to propensity matched controls from general car-
diac surgery patients found that the mortality risks in both
the groups was comparable, with higher risk of renal fail-
ure and stroke in the group receiving rFVIIa[57,61].
Recently, the same group in their observational study
compared the unadjusted and risk-adjusted adverse
events in cardiac surgery patients with refractory bleeding
that received or did not receive rFVIIa. They found that
when no adjustment was made, rFVIIa administration was
strongly associated with composite adverse events (OR
2.41; 95% CI 1.58–3.67). However, after risk adjustment
using propensity matching for other confounding factors
like red cell transfusion, CPB time, they found that rFVIIa
administration was no longer associated with composite
adverse events (OR 1.04; 95% CI 0.60–1.81)[58]
Although the timing of rFVIIa administration was not
strictly defined in our study, some have suggested that
rFVIIa would be better used earlier in the course of signif-
icant postoperative hemorrhage or after a dictated
number of transfusion units[32,58,67,69]
Dosing of rFVIIa for off-label settings is not standardized
and is evolving based partly on cost consideration and
also evidence that doses lower than the recommended
dose for hemophiliacs (i.e. 90 ug/kg) may be effective in
such settings. A recent study found that a median rFVIIa
dose of 17 ug/kg (Range: 11.1 ug/kg to 21.7 ug/kg)
showed satisfactory results in cardiac patients with intrac-
table bleeding [70]. Yet another study from Netherlands
found that rFVIIa dose of 40 ug/kg stopped bleeding in
seven patients who had uncontrolled bleeding after car-
diac surgery[71]. In our group, patients were administered
an average dose of 40 µg/kg at the first and the second
instance. A third dose at an average of 31 µg/kg was
administered to 4/15 patients. The amount of rFVIIa used
was based on the patient's clinical condition in consulta-
tion with the surgeon, the anesthesiologist and the trans-
fusion medicine team. We have previously reported a
catastrophic ECMO thrombosis in a patient who had
received rFVIIa along with prothrombin complex [29].
Based on the concerns for thrombotic complications,
patients are usually started with a lower dose of rFVIIa and
based on previously published guidelines[18]. Patients
that showed improvement after administration of one
dose of rFVIIa but continued to bleed may receive addi-
tional doses of rFVIIa after receiving additional conven-
tional blood therapy. No patients received more than
three doses of rFVIIa.
Conclusion
In our retrospective review of patients undergoing VAD
implantation or removal and OHT, we found that rFVIIa
appeared to be effective in reducing life-threatening bleed-
ing refractory to conventional hemostatic blood compo-
nent therapy. We also found that administration of rFVIIa
may be associated with significant decrease in blood loss
and blood component use. Nearly a third of our patients
had thromboembolic events, of which three were fatal.
Considering that this patients received rFVIIa after at least
two rounds of conventional hemostatic therapy failed to
stop bleeding with other predisposing clinical conditions
including life-threatening bleeding (i.e., with hyoper-
fusion and target organ injury) that would predispose
them to develop thromboembolic complications and a
higher mortality rate, a clear association with rFVIIa
administration cannot be made. Our data thus adds to the
growing literature regarding the use of rFVIIa in treatment
of refractory coagulopathy associated with non-coronary
complex cardiac surgeries. However, additional rand-
omized investigations to study the optimal timing, dosing
and associated thromboembolic risks of rFVIIa are
needed. In summary it can be concluded that rFVIIa
administration can be helpful in the treatment of patients
with life-threatening bleeding following complex non
coronary cardiac surgery.Journal of Cardiothoracic Surgery 2007, 2:32 http://www.cardiothoracicsurgery.org/content/2/1/32
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